| Gene symbol | HSPB1 | Synonyms | CMT2F, HEL-S-102, HMN2B, HMND3, HS.76067, HSP27, HSP28, Hsp25, SRP27 | Type of gene | protein-coding |
| Chromosome | 7 | Map location | 7q11.23 | dbXrefs | |
| Description | heat shock protein family B (small) member 1 | ||||
| GTO ID | GTC1396 |
| Trial ID | NCT01454089 |
| Disease | Bladder Cancer |
| Altered gene | Hsp27 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | OGX-427|Apatorsen |
| Co-treatment | Gemcitabine|Cisplatin|Carboplatin |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma |
| Year | 2011 |
| Country | Canada|France|Germany|Italy|Poland|Spain|United States |
| Company sponsor | Achieve Life Sciences |
| Other ID(s) | OGX-427-02 |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||